Methods of engineering transferrin receptor binding polypeptides

Inventors

Chen, Xiaocheng • Dennis, Mark S. • Kariolis, Mihalis • Silverman, Adam P. • SRIVASTAVA, Ankita • Watts, Ryan J. • Wells, Robert C. • Zuchero, Joy Yu

Assignees

Denali Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11912778-B2

Patent

Publication Date

2024-02-27

Expiration Date


Abstract

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Core Innovation

The invention relates to generating one or more variant polypeptides that specifically bind transferrin receptor protein and transport across the blood brain barrier. A contiguous surface exposed register of about 7 to 15 amino acids of a native polypeptide is identified for mutation, and the identified register of the native polypeptide does not bind transferrin receptor protein.

The method generates one or more polynucleotides encoding a library of sequence variants of the native polypeptide, with one or more mutations in the identified register. The polynucleotides are expressed to produce the library of sequence variants, the library is screened to identify one or more variant polypeptides that specifically bind transferrin receptor protein, and the variant polypeptides are isolated.

The isolated variant polypeptides specifically bind transferrin receptor protein and exhibit substantially improved brain uptake compared to the native polypeptide. The description further refers to substitutions into IgG Fc CH3 and/or CH2 domains to create a novel transferrin receptor binding site, along with sequence pattern options, transferrin competition, internalization/transcytosis-related assays, and in vivo brain pharmacokinetics/pharmacodynamics outcomes including Aβ40 reduction.

Claims Coverage

The independent claim coverage centers on 5 main features: identifying a contiguous surface exposed mutation register, generating an encoded library of sequence variants, expressing the polynucleotides, screening for transferrin receptor-binding variants, and isolating variants with improved brain uptake. Dependent refinements add register patterns, TfR selectivity constraints, and functional readouts.

Identifying a contiguous surface exposed mutation register

A method includes identifying a contiguous surface exposed register of about 7 to 15 amino acids of a native polypeptide for mutation.

Generating a library-encoding polynucleotide with mutations in the register

A method includes generating one or more polynucleotides comprising a nucleotide sequence that encodes for a library of sequence variants of the native polypeptide, wherein the nucleotide sequence encodes for one or more mutations in the identified register of the native polypeptide.

Expressing the polynucleotides to produce a library of sequence variants

A method includes expressing the one or more polynucleotides to produce the library of sequence variants.

Screening to identify transferrin receptor-binding variant polypeptides

A method includes screening the library of sequence variants to identify one or more variant polypeptides that specifically bind transferrin receptor protein, and isolating the variant polypeptides.

Register not binding transferrin receptor while variants improve brain uptake

The method provides that the identified register of the native polypeptide does not bind transferrin receptor protein, and that the isolated variant polypeptides exhibit substantially improved brain uptake compared to the native polypeptide.

The claim coverage combines mutation of a non-binding contiguous surface-exposed register, library generation and expression, screening for specific transferrin receptor binding, and isolation of variants that exhibit substantially improved brain uptake versus the native polypeptide.

Stated Advantages

The isolated variant polypeptides exhibit substantially improved brain uptake compared to the native polypeptide.

Improved brain uptake is described as more than 10-fold in dependent refinements.

Documented Applications

Transport across the blood brain barrier of variant polypeptides that specifically bind transferrin receptor protein.

Therapeutic use contexts for CNS, including neurological disease indications, CNS tumors, and autoimmune/inflammatory diseases.

Brain uptake supported by in vivo brain pharmacokinetics/pharmacodynamics outcomes including Aβ40 reduction.

Competition and internalization/transcytosis-related assays are documented to support TfR binding and related cellular/transport behavior.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.